Samarium lexidronam ( 153 Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma
2007; Taylor & Francis; Volume: 7; Issue: 11 Linguagem: Inglês
10.1586/14737140.7.11.1517
ISSN1744-8328
Autores Tópico(s)Radiopharmaceutical Chemistry and Applications
ResumoRadiation therapy can be an effective means to treat bone metastases, which occur in more than 50% of cancer patients. 153Samarium lexidronam (153Sm-EDTMP; Quadramet, Cytogen) is a radiopharmaceutical designed for deposition into bone metastases. Bone scans can identify patients that may benefit from targeted radiation therapy with 153Sm-EDTMP. As an unsealed source of radiation therapy, 153Sm-EDTMP is simple to administer: 1 mCi/kg is given in a similar fashion to a bone scan injection (99mTc-MDP bone scan injection is given at 0.2–0.35 mCi/kg. Therefore, both are administered intravenously. However, the radiation-absorbed dose and radiopharmaceutical energy are different). Nevertheless, despite simplicity of administration, 153Sm-EDTMP is underutilized for improving cancer pain in the skeleton. Repeated cycles and combined treatment with other modalities such as bisphosphonates, chemotherapy and/or external beam radiation are possible. 153Sm-EDTMP combined with bisphosphonates, chemotherapy and/or radiation may provide better palliation of bone metastases and also in bone-forming tumors (osteosarcoma). Encouraging experience using high-dose 153Sm-EDTMP for total marrow irradiation in hematologic malignancies involving the bones (e.g., myeloma or acute leukemia) is also reviewed.
Referência(s)